Antidepressants are among the most commonly prescribed and best-studied medications for fibromyalgia, and their benefit is largely independent of whether you have depression. Two antidepressants, duloxetine and milnacipran, carry specific FDA approval for fibromyalgia, while a third, the older tricyclic amitriptyline, has decades of clinical use behind it despite never receiving formal approval for the condition. The reason antidepressants help has less to do with mood than with how pain signals travel through the spinal cord and brain, a distinction that surprises many people hearing about these medications for the first time.
Why an Antidepressant Would Help With Pain
Fibromyalgia involves abnormal pain processing in the central nervous system. The brain and spinal cord amplify incoming pain signals while simultaneously failing to dampen them through what researchers call the descending pain modulation system. In a healthy nervous system, the brain sends inhibitory signals downward through the spinal cord to dial back pain. In fibromyalgia, that braking system does not work properly, leaving the volume on pain turned up far beyond what the actual tissue injury (if any) would warrant.1PubMed Central. Descending Pain Modulation in Fibromyalgia: A Short Review of Mechanisms and Biomarkers
Serotonin and norepinephrine are the two chemical messengers most involved in that descending brake. Antidepressants that boost one or both of these chemicals in the spinal cord can strengthen the brake and reduce pain transmission, quite apart from anything they do to mood. This is why drugs that act on both serotonin and norepinephrine tend to outperform those that target serotonin alone for fibromyalgia pain.2PubMed Central. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) for Treatment of Fibromyalgia: A Comprehensive Clinical Review
Duloxetine
Duloxetine (brand name Cymbalta) is the most widely prescribed antidepressant for fibromyalgia and the one with the deepest evidence base. A pooled analysis of four placebo-controlled trials found that after 12 weeks, duloxetine significantly reduced pain and improved global functioning, quality of life, and the ability to manage work and family responsibilities compared with placebo.3PubMed Central. Efficacy of Duloxetine in Patients With Fibromyalgia: Pooled Analysis of 4 Placebo-Controlled Clinical Trials A later systematic review and meta-analysis confirmed that duloxetine beat placebo across every measured outcome regardless of the dose used.4PubMed Central. Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis
One finding that clinicians lean on heavily is that duloxetine’s pain-relieving effect does not depend on whether you also have depression. An early trial showed that people without major depressive disorder got the same degree of pain relief as those who were depressed.5PubMed. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder A separate trial in women specifically confirmed that the reduction in pain was independent of any mood improvement.6PubMed. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder So if your doctor suggests duloxetine and you do not feel depressed, the recommendation still makes pharmacologic sense.
The typical starting dose is 30 mg daily, often increased to 60 mg. The most common side effects are nausea, dry mouth, constipation, and drowsiness, with nausea generally improving after the first few weeks.
Milnacipran
Milnacipran (brand name Savella in the United States) is the other SNRI with FDA approval for fibromyalgia.7PubMed Central. Milnacipran for the Treatment of Fibromyalgia It leans more heavily on norepinephrine reuptake than duloxetine does, which may explain why some people respond to one but not the other. In a 15-week trial, both the 100 mg and 200 mg daily doses produced significantly more composite responders than placebo, and pain improvements showed up within the first week of treatment. Patients also reported better physical functioning and less fatigue.8PubMed. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial
Fatigue is one of the most debilitating fibromyalgia symptoms, and milnacipran appears to address it through more than just pain relief. A pooled analysis of three trials found that roughly a quarter of the fatigue improvement seen with milnacipran came from a direct drug effect rather than an indirect consequence of feeling less pain.9PubMed. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials That distinction matters if fatigue is your dominant complaint.
Milnacipran is not approved for fibromyalgia in Europe, where it was originally marketed solely as an antidepressant. If you are outside the United States, your doctor may know the drug but not associate it with pain treatment.
Amitriptyline and Older Tricyclics
Long before duloxetine or milnacipran existed, clinicians were prescribing low-dose amitriptyline for fibromyalgia. It remains one of the most recommended first-line drugs in multiple international guidelines.10PubMed. Amitriptyline for the treatment of fibromyalgia: a comprehensive review The typical dose range is much lower than what would be used for depression, usually between 10 mg and 25 mg taken at bedtime.
The evidence, however, is mixed in quality. A Cochrane review found no high-quality evidence for amitriptyline in fibromyalgia. Using lower-tier data, the number needed to treat for at least a 50 percent pain reduction was roughly four, meaning about one in four people treated gets a meaningful benefit that would not have occurred with placebo.11PubMed Central. Amitriptyline for fibromyalgia in adults A systematic review of randomized trials found that the 25 mg dose showed benefit at six to eight weeks but that the effect faded by 12 weeks, and the 50 mg dose did not outperform placebo at all.12Rheumatology. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy
The paradox of amitriptyline is that its real-world popularity far outstrips its trial evidence. Clinicians continue to prescribe it partly because it is inexpensive, partly because its sedating effects help with the sleep disruption that plagues most fibromyalgia patients, and partly because decades of clinical experience have built confidence that the trials do not fully capture. Its main downsides are anticholinergic side effects: dry mouth, morning grogginess, constipation, and weight gain, which become more troublesome at higher doses.
How Different Antidepressant Classes Compare
Not all antidepressants are equal for fibromyalgia. A meta-analysis published in JAMA reported that the effect sizes for pain reduction were large for tricyclics, medium for monoamine oxidase inhibitors, and small for both SSRIs and SNRIs.13JAMA. Treatment of Fibromyalgia Syndrome With Antidepressants: A Meta-analysis That ranking surprised some researchers, because SNRIs are the drugs that actually earned FDA approval. A separate meta-analysis found that roughly 48 percent of patients on tricyclics achieved at least a 30 percent pain reduction, compared with about 42 percent on SNRIs and 36 percent on SSRIs.14PubMed. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis
SSRIs like fluoxetine and paroxetine do show some benefit for pain, sleep, and quality of life, but the effects are consistently smaller than what you get from drugs that also boost norepinephrine. A systematic review of antidepressant trials noted that most SSRIs tested showed positive results, with the exceptions of citalopram and one paroxetine trial.15PubMed. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome If you are already taking an SSRI for anxiety or depression and your fibromyalgia pain is not well controlled, switching to or adding an SNRI is a conversation worth having with your prescriber.
Off-Label Alternatives
When the approved options fail or cause intolerable side effects, clinicians sometimes turn to antidepressants that were never formally tested in large fibromyalgia programs but have properties that make them plausible candidates.
Mirtazapine, which works through a different mechanism than SSRIs or SNRIs, showed a statistically significant reduction in pain scores compared with placebo in a Japanese phase IIa trial, with about 46 percent of patients achieving at least a 30 percent pain reduction versus 31 percent on placebo.16PubMed Central. Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan A Cochrane review, however, concluded that mirtazapine is unlikely to produce substantial pain relief for most people and noted that drowsiness, weight gain, and potential liver effects are real concerns. The review suggested mirtazapine might be considered if established options have failed, particularly since it does not cause the gastrointestinal upset that drives many people off duloxetine or milnacipran.17Cochrane Database of Systematic Reviews. Mirtazapine for treating fibromyalgia in adults
Trazodone is another option that sometimes appears on treatment plans, mainly because of its strong sedating properties. An open-label 12-week study found large improvements in sleep quality and moderate improvements in overall fibromyalgia impact, anxiety, depression, and pain interference with daily activities.18PubMed Central. Trazodone for the treatment of fibromyalgia: an open-label, 12-week study Without a placebo comparison, though, that evidence is weaker. Trazodone tends to be used when sleep disturbance is the primary driver of disability rather than pain itself.
Combining an Antidepressant With Pregabalin
Pregabalin (Lyrica) is the third FDA-approved fibromyalgia drug, and it works through a completely different mechanism than antidepressants. Naturally, researchers have tested what happens when you combine the two approaches. In a randomized crossover trial, patients who took duloxetine plus pregabalin together reported daily pain scores of about 3.7 on a 10-point scale, compared with roughly 4.1 on duloxetine alone, 5.0 on pregabalin alone, and 5.1 on placebo. About 68 percent of patients on the combination reported at least moderate global pain relief, compared with 42 percent on duloxetine alone and 39 percent on pregabalin alone.19PubMed. Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial
Sleep improved substantially with the combination as well, which is not surprising given that pregabalin is sedating on its own. The trade-off was more drowsiness. Another trial compared pregabalin paired with different antidepressants and found that pregabalin plus paroxetine produced better tolerability and mood outcomes than pregabalin plus amitriptyline or venlafaxine, with fewer side effects like dry mouth and elevated blood pressure.20PubMed. Comparative Efficacy of Newer Antidepressants in Combination with Pregabalin for Fibromyalgia Syndrome: A Controlled, Randomized Study Combination therapy is increasingly seen as a practical reality for fibromyalgia, and the network of pharmacological plus non-pharmacological approaches together appears to produce better results than any single drug.21Annals of the Rheumatic Diseases. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis
Who Responds and Who Doesn’t
One of the frustrating realities of fibromyalgia treatment is that no drug works for everyone, and there is no blood test that predicts who will benefit. Researchers are beginning to identify patterns, though. A study looking at chronobiological variables found that people with greater circadian rhythm disruption, worse sleep quality, and lower morning energy were more likely to be nonresponders to SNRIs.22PubMed Central. Chronobiological variables predict non-response to serotonin and noradrenaline reuptake inhibitors in fibromyalgia: a cross-sectional study In plain terms, the more your body clock is disrupted, the less likely an SNRI alone will get the job done.
Other predictors of nonresponse to SNRIs include insulin resistance, co-existing anxiety disorders, and personality disorders.23Polish Archives of Internal Medicine. Predictors of treatment response to serotonin and noradrenaline reuptake inhibitors in fibromyalgia Interestingly, a history of early-life abuse, which is more common in fibromyalgia patients than in the general population, did not predict a worse response to the SSRI paroxetine in one post-hoc analysis.24PubMed. History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release That last point matters because some patients worry that a trauma history makes medication less likely to help, but the data do not support that concern.
What Happens When You Stop
Fibromyalgia is a chronic condition, and stopping an antidepressant that has been helping raises obvious questions. A study that abruptly switched milnacipran patients to placebo found that within two weeks, pain, functioning, and global status all worsened compared with patients who stayed on the drug. The proportion of composite responders dropped from about 32 percent in those continuing treatment to 22 percent in those who stopped. On a positive note, newly emergent side effects during the switch were not more common in the discontinuation group, and vital signs returned to baseline quickly.25PubMed. Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia
One small observational study raised a different concern. After 12 months, fibromyalgia patients who stayed on antidepressants reported worse fibromyalgia impact and lower quality-of-life scores than a comparison group not taking antidepressants.26Clinical Practice & Epidemiology in Mental Health. The Use of Antidepressants in the Long-Term Treatment Should not Improve the Impact of Fibromyalgia on Quality of Life That finding is hard to interpret because the groups were not randomly assigned; the patients taking antidepressants may have had more severe fibromyalgia to begin with, which is precisely why they were prescribed medication. Still, it underscores the fact that most clinical trials last only three to six months, and long-term data on antidepressants for fibromyalgia remain thin. If your medication feels less effective over time, that is worth discussing with your doctor rather than simply increasing the dose on your own.
Fibromyalgia in Adolescents
Juvenile fibromyalgia exists, and it creates a tricky prescribing gap. No medication is currently approved for fibromyalgia in people under 18. A randomized trial of duloxetine in adolescents with juvenile fibromyalgia missed its primary endpoint: the mean change in pain severity was not statistically different between duloxetine and placebo. However, significantly more patients on duloxetine achieved at least a 30 percent and 50 percent reduction in pain severity when measured as responder rates rather than averages. The safety profile was consistent with what has been seen in other pediatric duloxetine trials.27PubMed Central. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial In practice, prescribers sometimes use duloxetine or amitriptyline off-label in teens, but the evidence base is slim, and most guidelines emphasize exercise and cognitive-behavioral therapy first for younger patients.
Where International Guidelines Diverge
If you read fibromyalgia guidelines from different countries, you will notice they do not fully agree on the role of antidepressants. The American Pain Society, Canadian Pain Society, and the German medical societies all gave top-tier recommendations to amitriptyline alongside aerobic exercise, cognitive-behavioral therapy, and multicomponent treatment programs.28PubMed. Evidenced-Based Guidelines on the Treatment of Fibromyalgia Patients: Are They Consistent and If Not, Why Not? Have Effective Psychological Treatments Been Overlooked? The most recent EULAR guidelines from Europe, by contrast, pulled back from pharmacotherapy and elevated exercise to the highest level of recommendation, a reversal from EULAR’s own 2008 guidelines that had favored drugs.29PubMed Central. Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology
The disagreement comes down partly to how different panels weigh evidence. Panels that heavily discount low-quality trials (which describes most of the amitriptyline literature) end up less enthusiastic about it. Panels that give weight to clinical experience and decades of use rank it higher. For patients, the practical takeaway is that an antidepressant alone is rarely the whole answer. Every major guideline converges on the idea that exercise, psychological strategies, and medication work best together, not as alternatives. A network meta-analysis of both pharmacological and non-pharmacological interventions concluded that combining SNRIs or pregabalin with multicomponent therapy, aerobic exercise, and cognitive-behavioral therapy appeared to be the most promising overall strategy.30Annals of the Rheumatic Diseases. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis
Practical Decisions When Starting Treatment
Choosing between the available antidepressants usually comes down to your symptom profile and what side effects you can tolerate. If pain and depression are both prominent, duloxetine covers both effectively. If fatigue dominates and you want a drug with direct fatigue-reducing properties, milnacipran has the clearest evidence on that front. If sleep is your biggest problem and you want an inexpensive option, low-dose amitriptyline at bedtime can be a reasonable starting point, though the evidence weakens past the two-month mark. If you cannot tolerate nausea from SNRIs, mirtazapine becomes a fallback worth considering despite its less robust pain data.
Expect to give any antidepressant at least four to six weeks before judging whether it is working. Some studies have shown early pain improvement within the first week, but the full spectrum of benefits on functioning, fatigue, and sleep typically takes longer to develop. And because response rates across all classes hover somewhere between a third and half of patients, the possibility of needing to try more than one drug is normal, not a sign that your fibromyalgia is untreatable. The goal is usually meaningful improvement, not the elimination of all symptoms, and combining medication with regular aerobic exercise tends to push outcomes further than either approach alone.